Literature DB >> 17611870

Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis.

M Loy1, E Perra, A Melis, M E Cianchetti, M Piga, A Serra, G Pinna, S Mariotti.   

Abstract

BACKGROUND: Amiodarone-induced thyrotoxicosis (AIT) may be caused by excessive thyroidal hormone synthesis and release (type 1) or by a destructive process (type 2). This differentiation is considered essential for therapeutic choice.
PURPOSE: To evaluate the utility of color-flow Doppler sonography (CFDS) in the differential diagnosis and management of AIT.
MATERIAL AND METHODS: The clinical and laboratory data, thyroid sonography (grayscale sonography [GSS], CFDS), thyroid radioiodine uptake (RAIU) and thyroid scintigraphy, treatment, and clinical outcome were retrospectively reviewed in 21 AIT patients. The CFDS pattern of thyroid nodules was separately described from that of the perinodular parenchyma, and AIT was classified as type 1 (increased blood flow) or type 2 (low/no blood flow). Type 1 AIT patients were treated with methimazole (alone or associated with potassium perchlorate), while type 2 patients were treated with prednisone or amiodarone withdrawal alone.
RESULTS: Eleven patients with increased blood flow were considered as type 1, and 10 with low/no blood flow as type 2. Ten of the 11 patients in the first group showed a hypervascular nodular pattern, while one showed a hypervascular parenchymal pattern. Clinical diagnoses were toxic nodular goiter and Graves' disease, respectively. Of the 10 patients with low/no blood flow, six had normal thyroid volume, three small diffuse goiter, and one small multinodular goiter. The clinical outcome showed that 20 of the 21 patients were treatment responsive.
CONCLUSION: CFDS is a useful tool in the differential diagnosis of AIT. This differentiation appeared to be of clinical relevance as regards therapeutic choice. Separate evaluation of parenchymal blood flow from that of nodules may prove beneficial in the diagnosis of underlying thyroid diseases in patients with type 1 AIT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611870     DOI: 10.1080/02841850701342138

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  11 in total

1.  Thyroid gland: use of glucocorticoids in amiodarone-induced thyrotoxicosis.

Authors:  Mark P J Vanderpump
Journal:  Nat Rev Endocrinol       Date:  2009-12       Impact factor: 43.330

2.  Role of color Doppler in differentiation of Graves' disease and thyroiditis in thyrotoxicosis.

Authors:  Ragab Hani Donkol; Aml Mohamed Nada; Sami Boughattas
Journal:  World J Radiol       Date:  2013-04-28

Review 3.  Amiodarone and the thyroid: a 2012 update.

Authors:  F Bogazzi; L Tomisti; L Bartalena; F Aghini-Lombardi; E Martino
Journal:  J Endocrinol Invest       Date:  2012-03-19       Impact factor: 4.256

4.  2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction.

Authors:  Luigi Bartalena; Fausto Bogazzi; Luca Chiovato; Alicja Hubalewska-Dydejczyk; Thera P Links; Mark Vanderpump
Journal:  Eur Thyroid J       Date:  2018-02-14

5.  Evaluation of 99mTc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis.

Authors:  Junqi Wang; Ruiguo Zhang
Journal:  Br J Radiol       Date:  2017-01-20       Impact factor: 3.039

6.  Scintigraphic Profile of Thyrotoxicosis Patients and Correlation with Biochemical and Sonological Findings.

Authors:  Anil Kumar Avs; Abhish Mohan; P G Kumar; Pankaj Puri
Journal:  J Clin Diagn Res       Date:  2017-05-01

Review 7.  Emerging technologies and their impact on regulatory science.

Authors:  Elke Anklam; Martin Iain Bahl; Robert Ball; Richard D Beger; Jonathan Cohen; Suzanne Fitzpatrick; Philippe Girard; Blanka Halamoda-Kenzaoui; Denise Hinton; Akihiko Hirose; Arnd Hoeveler; Masamitsu Honma; Marta Hugas; Seichi Ishida; George En Kass; Hajime Kojima; Ira Krefting; Serguei Liachenko; Yan Liu; Shane Masters; Uwe Marx; Timothy McCarthy; Tim Mercer; Anil Patri; Carmen Pelaez; Munir Pirmohamed; Stefan Platz; Alexandre Js Ribeiro; Joseph V Rodricks; Ivan Rusyn; Reza M Salek; Reinhilde Schoonjans; Primal Silva; Clive N Svendsen; Susan Sumner; Kyung Sung; Danilo Tagle; Li Tong; Weida Tong; Janny van den Eijnden-van-Raaij; Neil Vary; Tao Wang; John Waterton; May Wang; Hairuo Wen; David Wishart; Yinyin Yuan; William Slikker
Journal:  Exp Biol Med (Maywood)       Date:  2021-11-16

8.  Plasma Beta-Glucuronidase Activity: A Novel Tool to Distinguish Type 1 from Type 2 Amiodarone-Induced Thyrotoxicosis?

Authors:  Georgios K Markantes; Marina A Michalaki; George A Vagenakis; Fotini N Lamari; Efthymia Pitsi; Maria Eliopoulou; Nicholas G Beratis; Kostas B Markou
Journal:  Eur Thyroid J       Date:  2019-07-15

9.  Amiodarone-induced thyrotoxic thyroiditis: a diagnostic and therapeutic challenge.

Authors:  Umang Barvalia; Barkha Amlani; Ram Pathak
Journal:  Case Rep Med       Date:  2014-11-12

10.  Anatomical and functional imaging in endocrine hypertension.

Authors:  Vikas Chaudhary; Shahina Bano
Journal:  Indian J Endocrinol Metab       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.